SANTA CLARA, Calif.–To meet the growing demand for preemptive pharmacogenomic risk factor screening that may one day aid drug prescription practices, Thermo Fisher Scientific today introduced PharmacoScan Solution, a new microarray-based research tool that contains pharmacogenomic content with relevant markers involved in absorption, distribution, metabolism and excretion (ADME) pathways of commonly prescribed medicines. The PharmacoScan Solution will be highlighted today during the Pharmacogenomics Research Network (PGRN) symposium held in concert with the 2016 American Society of Human Genetics (ASHG) Annual Meeting, October 18–22 in Vancouver, Canada.

Pharmacogenomics (PGx) research is aimed at increasing drug development outcome efficiency and reducing adverse drug reactions. In the United States alone, adverse drug reactions cause the death, hospitalization or serious injury of more than 2 million people each year. PharmacoScan Solution addresses the pharmacogenomic profiling research objectives